Price
No data yet.
Social Signal Score
Revenue
$8.1K-86.26%Company Profile
- CEO
- Robert Huizinga
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Beta
- 0.31
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -28.60
Financials
Revenue
$8.1K-86.3%Net Income
$-834.0KEBITDA
$-775.8KFree Cash Flow
$-634.6KEPS (diluted)
$-0.00Shares Outstanding (diluted)
205.06M+484.9%Operating Expenses
$777.2KCash & Debt
$855.1KReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $427.5K | $-2.72M | $-0.02 |
| 2024 | $2.08M | $6.10M | $-0.02 |
| 2023 | $149.0K | $-5.03M | $-0.04 |
| 2022 | $2.67M | $-3.89M | $-0.03 |
| 2021 | $1.61M | $-4.60M | $-0.04 |
| 2020 | $1.34M | $-3.72M | $-0.03 |
| 2019 | $1.69M | $-960.2K | $-0.01 |
| 2018 | $506.3K | $-3.26M | $-0.04 |
| 2017 | $1.04M | $-2.79M | $-0.05 |
| 2016 | $244.8K | $-2.55M | $-0.07 |
| 2015 | $104.6K | $-1.71M | $-0.08 |
| 2014 | $41.9K | $-1.61M | $-0.08 |
| 2013 | $159.9K | $-1.45M | $-0.08 |
| 2012 | $0.00 | $-1.46M | $-0.10 |
Valuation
KNBIFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·2d ago·Neutral
Kane Engages Independent Trading Group as Market Maker Agreement intended to support an orderly market and improve liquidity in Kane Biotech's common shares Agreement intended to support an orderly market and improve liquidity in Kane Biotech's common shares
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Kane Biotech Signs Distribution Agreement with The Stevens Company Expands Kane Biotech's commercial footprint and access to the revyve ® product line across Canada
View source ↗ - Newsglobenewswire.com·5d ago·Negative
Kane to Showcase revyve® at Wounds Canada National Hybrid Conference Engaging Canadian wound-care professionals, presenting data and discussing biofilm management in clinical practice WINNIPEG, Manitoba, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it will attend the Wounds Canada National Hybrid Confe
View source ↗ - Newsglobenewswire.com·5d ago·Negative
Kane Launches New Corporate Brand and Redesigned Website Refreshed identity reflects Kane's focus on clinical biofilm science, advanced wound care and commercialization Refreshed identity reflects Kane's focus on clinical biofilm science, advanced wound care and commercialization
View source ↗ - Newsglobenewswire.com·7d ago·Negative
Kane Biotech Announces $250,000 Insider Loan Unsecured, non-interest-bearing loan provides additional working capital support Unsecured, non-interest-bearing loan provides additional working capital support
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Kane Biotech to Present Clinical Data and Showcase revyve® Product Line at SAWC Fall 2026 Company to engage with wound-care professionals and meet with existing and prospective distribution partners Company to engage with wound-care professionals and meet with existing and prospective distribution partners
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Kane Biotech to Host Commercial Update Webcast on September 16 Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
Kane Biotech Announces Second Quarter 2026 Financial Results WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.
View source ↗
Earnings
Thu, Nov 26(in 5 weeks)
Estimates and results for KNBIF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in KNBIF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.